Know Cancer

or
forgot password

Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment


Phase 1/Phase 2
20 Years
N/A
Not Enrolling
Both
Pancreatic Cancer

Thank you

Trial Information

Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment


Inclusion Criteria:



- Subjects with unresectable locally advanced or metastatic pancreatic cancer

- KPS > 70%

- Life expectancy of at least 3 months

Exclusion Criteria:

- received previous chemotherapy for the current indication

- received previous radiotherapy for the current indication

- Currently receiving chemotherapy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Safety, Pharmacokinetics

Principal Investigator

Tim Meyer, PhD, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Royal Free Hospital

Authority:

United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:

01010106E

NCT ID:

NCT00288925

Start Date:

September 2005

Completion Date:

Related Keywords:

  • Pancreatic Cancer
  • Pancreatic Neoplasms

Name

Location